Neurolief Secures $6M Investment to Expand Brain Neuromodulation Therapy Post FDA Approval Neurolief announces a $6 million investment to broaden access to its Proliv™Rx brain neuromodulation therapy, post FDA approval, for depression patients.

Neurolief Secures $6M Investment to Expand Brain Neuromodulation Therapy Post FDA Approval #USA #Coral_Springs #Neurolief #BrainsWay #ProlivRx

Neurolief's MOOD Study Launches New Hope for Major Depressive Disorder Treatment Neurolief's recently published MOOD study paves the way for innovative neuromodulation therapy targeting Major Depressive Disorder, showing promising results.

Neurolief's MOOD Study Launches New Hope for Major Depressive Disorder Treatment #USA #Depression #Coral_Springs #Neurolief #ProlivRx